Cipla's generic of GSK's Advair for asthma marks expansion into Europe

1 September 2014

Indian generic drugmaker Cipla has entered the respiratory market in Germany and Sweden with its Serroflo (salmeterol/fluticasone MDI).

Serroflo is the generic version of UK pharma major GlaxoSmithKline (LSE: GSK)’s Advair, and aside from Croatia where salmeterol/fluticasone is already available as Duohal, will mark Cipla’s first entry into the European health care market.

Advair brought in sales of $8.25 billion in 2013, and Mylan has plans to file an application to the US Food and Drug Administration for its Advair generic in the third quarter of next year to begin selling in 2016. Even though the drug itself is out of patent, GlaxoSmithKline still has ownership of the dispensing inhalers, with the dispenser for the powder version expiring in 2016, and the aerosol in 2025. The FDA has issued guidance on the necessary characteristics for a generic device in order for it to not infringe on GlaxoSmithKline’s patent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK